| __timestamp | Celldex Therapeutics, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 2043000 |
| Thursday, January 1, 2015 | 4011000 | 3895000 |
| Friday, January 1, 2016 | 102026000 | 6552000 |
| Sunday, January 1, 2017 | 96171000 | 15066000 |
| Monday, January 1, 2018 | 66449000 | 26348000 |
| Tuesday, January 1, 2019 | 42672000 | 33097000 |
| Wednesday, January 1, 2020 | 42534000 | 36272000 |
| Friday, January 1, 2021 | 3068000 | 52873000 |
| Saturday, January 1, 2022 | 1400000 | 57909000 |
| Sunday, January 1, 2023 | 3008000 | 72547000 |
| Monday, January 1, 2024 | 0 |
Data in motion
In the competitive world of biotechnology, understanding cost structures is crucial. This chart compares the cost of revenue for Exelixis, Inc. and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Celldex Therapeutics experienced a significant decline in cost of revenue, dropping by approximately 97% from 2014 to 2023. In contrast, Exelixis, Inc. saw a dramatic increase, with costs rising by over 3,400% during the same period. This divergence highlights the differing strategic paths and operational efficiencies of these two companies. While Celldex has managed to streamline its operations, Exelixis has expanded, possibly investing more in production and development. This data provides a fascinating insight into how two companies in the same industry can evolve differently over time, reflecting their unique business strategies and market responses.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Sanofi vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Exelixis, Inc.
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Exelixis, Inc. vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Galapagos NV
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.